secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001558370-23-005393
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio appoints Kevin Brennan as SVP, Finance and Accounting, principal financial officer
--------------------------------------------------------------------------------

- Kevin Brennan joined Xilio on March 30, 2023 as SVP, Finance and Accounting and principal financial/accounting officer.
- Brennan receives annual base salary of $370,000, target bonus of 35% of base salary.
- Granted stock option to purchase 55,000 shares; vests 25% on first anniversary, 75% monthly over 3 years.
- Board adopted amended and restated bylaws updating stockholder meeting procedures and universal proxy rules.
- Bylaw amendments also include enhanced advance notice disclosure requirements and technical changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023005393/0001558370-23-005393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023005393/xlo-20230328x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-005393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer